JP6541350B2 - 抗ｃｘｃｒ４抗体による血液悪性腫瘍の処置 - Google Patents

抗ｃｘｃｒ４抗体による血液悪性腫瘍の処置 Download PDF

Info

Publication number
JP6541350B2
JP6541350B2 JP2014541315A JP2014541315A JP6541350B2 JP 6541350 B2 JP6541350 B2 JP 6541350B2 JP 2014541315 A JP2014541315 A JP 2014541315A JP 2014541315 A JP2014541315 A JP 2014541315A JP 6541350 B2 JP6541350 B2 JP 6541350B2
Authority
JP
Japan
Prior art keywords
cxcr4
antibody
cells
seq
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014541315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014533279A (ja
JP2014533279A5 (enExample
Inventor
ミッシェル・アール・カーン
チン・パン
ジョセフィーヌ・エム・カルダレッリ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2014533279A publication Critical patent/JP2014533279A/ja
Publication of JP2014533279A5 publication Critical patent/JP2014533279A5/ja
Application granted granted Critical
Publication of JP6541350B2 publication Critical patent/JP6541350B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2014541315A 2011-11-09 2012-11-09 抗ｃｘｃｒ４抗体による血液悪性腫瘍の処置 Expired - Fee Related JP6541350B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161557815P 2011-11-09 2011-11-09
US61/557,815 2011-11-09
US201161569113P 2011-12-09 2011-12-09
US61/569,113 2011-12-09
PCT/US2012/064395 WO2013071068A2 (en) 2011-11-09 2012-11-09 Treatment of hematologic malignancies with an anti-cxcr4 antibody

Publications (3)

Publication Number Publication Date
JP2014533279A JP2014533279A (ja) 2014-12-11
JP2014533279A5 JP2014533279A5 (enExample) 2015-12-24
JP6541350B2 true JP6541350B2 (ja) 2019-07-10

Family

ID=47179025

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014541315A Expired - Fee Related JP6541350B2 (ja) 2011-11-09 2012-11-09 抗ｃｘｃｒ４抗体による血液悪性腫瘍の処置

Country Status (24)

Country Link
US (2) US10428151B2 (enExample)
EP (1) EP2776032B1 (enExample)
JP (1) JP6541350B2 (enExample)
KR (1) KR102024957B1 (enExample)
CN (1) CN104039320B (enExample)
AU (1) AU2012335553B2 (enExample)
BR (1) BR112014011144A2 (enExample)
CA (1) CA2855155A1 (enExample)
CY (1) CY1121331T1 (enExample)
DK (1) DK2776032T3 (enExample)
EA (1) EA026153B1 (enExample)
ES (1) ES2705001T3 (enExample)
HR (1) HRP20182183T1 (enExample)
HU (1) HUE043001T2 (enExample)
IL (1) IL232517B (enExample)
LT (1) LT2776032T (enExample)
MX (1) MX357100B (enExample)
PL (1) PL2776032T3 (enExample)
PT (1) PT2776032T (enExample)
RS (1) RS58102B1 (enExample)
SG (1) SG11201401386XA (enExample)
SI (1) SI2776032T1 (enExample)
SM (1) SMT201900026T1 (enExample)
WO (1) WO2013071068A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018836B1 (ru) * 2006-10-02 2013-11-29 Медарекс, Л.Л.К. Человеческие антитела, которые связываются с cxcr4, и их применение
ES2624981T3 (es) 2011-07-01 2017-07-18 Dana-Farber Cancer Institute, Inc. Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario
CA2920377A1 (en) * 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
CA2922398C (en) * 2013-09-12 2023-08-29 Dana-Farber Cancer Institute, Inc. Methods for evaluating and treating waldenstrom's macroglobulinemia
ES2742079T3 (es) * 2013-11-06 2020-02-13 Bristol Myers Squibb Co Tratamiento de macroglobulinemia de Waldenström asociada a C1013G/CXCR4 con un anticuerpo anti-CXCR4
EP3077001B1 (en) 2013-12-06 2020-04-15 Dana-Farber Cancer Institute, Inc. Methods to distinguish waldenström's macroglobulinemia from igm monoclonal gammopathy of undetermined significance
AU2014361798B2 (en) 2013-12-13 2020-06-11 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
CN106062002B (zh) * 2013-12-17 2021-05-04 埃姆医疗有限公司 抵抗骨髓增生障碍或淋巴组织增生障碍的手段和方法
WO2015118538A1 (en) 2014-02-06 2015-08-13 Yeda Research And Development Co. Ltd. Anti cd84 antibodies, compositions comprising same and uses thereof
CN106794219A (zh) * 2014-02-19 2017-05-31 北京迈康斯德医药技术有限公司 趋化因子受体拮抗体及其联合疗法
EP3242685B1 (en) * 2015-01-09 2022-05-04 AdAlta Limited Cxcr4 binding molecules
SG11201708223QA (en) 2015-04-17 2017-11-29 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
CN108026173A (zh) 2015-06-12 2018-05-11 百时美施贵宝公司 通过联合阻断pd-1和cxcr4信号传导途径治疗癌症
CN116196426A (zh) 2015-07-16 2023-06-02 百欧肯治疗有限公司 治疗癌症的组合物及方法
JP6933379B2 (ja) * 2015-09-24 2021-09-08 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 転移を低減するための方法および組成物
EP3373929A4 (en) * 2015-11-09 2019-07-03 The General Hospital Corporation d/b/a Massachusetts General Hospital UNIT DOSE FORMULATIONS FOR USE AS ANTI-FUGETACTIC AGENT
AU2017222495B2 (en) * 2016-02-23 2019-08-08 Biolinerx Ltd. Methods of treating acute myeloid leukemia
CN109152781A (zh) 2016-04-29 2019-01-04 达纳-法伯癌症研究所有限公司 作为myd88突变疾病中的治疗靶标的hck
JP7169195B2 (ja) 2016-05-20 2022-11-10 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用
US20190175557A1 (en) * 2016-06-16 2019-06-13 Centre National De La Recherche Scientifique Compounds useful for decreasing interferon level
NZ789594A (en) 2016-06-20 2025-07-25 Kymab Ltd Anti-PD-L1 antibodies
CN110234352A (zh) * 2017-01-31 2019-09-13 Msm蛋白质技术公司 抗cxcr4抗体
KR102003179B1 (ko) * 2017-02-21 2019-07-23 쿠라 온콜로지, 인크. 파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법
AU2018243754B2 (en) 2017-03-31 2025-04-10 Bristol-Myers Squibb Company Methods of treating tumor
KR20200064132A (ko) 2017-10-15 2020-06-05 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
WO2019113456A1 (en) * 2017-12-08 2019-06-13 The Medical College Of Wisconsin, Inc. Chemokine variants as immune stimulants
US20230181635A1 (en) * 2018-03-13 2023-06-15 Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy
EP3768715A1 (en) 2018-03-23 2021-01-27 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
US20210024873A1 (en) 2018-03-27 2021-01-28 Bristol-Myers Squibb Company Real-time monitoring of protein concentration using ultraviolet signal
WO2019191676A1 (en) 2018-03-30 2019-10-03 Bristol-Myers Squibb Company Methods of treating tumor
US20220135619A1 (en) 2019-02-24 2022-05-05 Bristol-Myers Squibb Company Methods of isolating a protein
CN114245869A (zh) 2019-05-23 2022-03-25 百时美施贵宝公司 监测细胞培养基的方法
KR20230080460A (ko) 2020-10-05 2023-06-07 브리스톨-마이어스 스큅 컴퍼니 단백질을 농축시키는 방법
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
US20250188152A1 (en) 2022-03-09 2025-06-12 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
TW202444754A (zh) * 2023-01-30 2024-11-16 英商凱麥博有限公司 抗體
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
CN119119196B (zh) * 2024-08-01 2025-09-09 青岛大学 一种基于Motixafortide-喜树碱缀合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JP3367581B2 (ja) 1993-10-14 2003-01-14 小野薬品工業株式会社 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
CN101940189A (zh) 2000-11-30 2011-01-12 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
US7674618B2 (en) 2003-09-04 2010-03-09 Medarex, Inc. Expression vector
EP1871807B1 (en) 2005-02-18 2012-11-28 Dana-Farber Cancer Institute, Inc. Antibodies against cxcr4 and methods of use thereof
US8569280B2 (en) * 2005-04-25 2013-10-29 Immune Disease Institute Methods for the treatment of multiple myeloma
DK2029155T3 (en) * 2006-02-28 2016-08-01 Pharma Mar Sa IMPROVED treatment of multiple myeloma
EA018836B1 (ru) * 2006-10-02 2013-11-29 Медарекс, Л.Л.К. Человеческие антитела, которые связываются с cxcr4, и их применение
FR2915102B1 (fr) 2007-04-23 2014-05-16 Pf Medicament Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
MX2010012435A (es) * 2008-05-14 2011-05-03 Lilly Co Eli Anticuerpos anti-cxcr4.
WO2010043650A2 (en) 2008-10-14 2010-04-22 Ablynx Nv Amino acid sequences directed against cellular receptors for viruses and bacteria
EP2405916B1 (en) * 2009-03-12 2018-02-07 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
AR076590A1 (es) * 2009-05-19 2011-06-22 Vivia Biotech Sl Metodos para proveer pruebas medicinales personalizada ex vivo para neoplasmas hematologicos
EA201390144A1 (ru) 2010-08-20 2013-06-28 Серулин Фарма Инк. Конъюгаты терапевтический пептид-полимер, частицы, композиции и связанные с ними способы

Also Published As

Publication number Publication date
SMT201900026T1 (it) 2019-05-10
RS58102B1 (sr) 2019-02-28
EA201490957A1 (ru) 2014-08-29
EA026153B1 (ru) 2017-03-31
US10428151B2 (en) 2019-10-01
MX2014005267A (es) 2014-07-28
CA2855155A1 (en) 2013-05-16
IL232517A0 (en) 2014-06-30
WO2013071068A2 (en) 2013-05-16
JP2014533279A (ja) 2014-12-11
LT2776032T (lt) 2018-12-10
US20200231683A1 (en) 2020-07-23
CY1121331T1 (el) 2020-05-29
EP2776032A2 (en) 2014-09-17
DK2776032T3 (en) 2019-02-04
SG11201401386XA (en) 2014-10-30
WO2013071068A3 (en) 2013-07-18
KR102024957B1 (ko) 2019-09-24
PT2776032T (pt) 2019-01-21
US20140322208A1 (en) 2014-10-30
IL232517B (en) 2018-05-31
MX357100B (es) 2018-06-26
PL2776032T3 (pl) 2019-03-29
CN104039320B (zh) 2019-10-15
CN104039320A (zh) 2014-09-10
AU2012335553A1 (en) 2014-07-03
AU2012335553B2 (en) 2017-09-21
HRP20182183T1 (hr) 2019-02-22
KR20140093945A (ko) 2014-07-29
ES2705001T3 (es) 2019-03-21
EP2776032B1 (en) 2018-10-17
HUE043001T2 (hu) 2019-07-29
BR112014011144A2 (pt) 2017-05-16
SI2776032T1 (sl) 2018-12-31

Similar Documents

Publication Publication Date Title
JP6541350B2 (ja) 抗ｃｘｃｒ４抗体による血液悪性腫瘍の処置
US11103579B2 (en) Combination of DR5 agonist and anti-PD-1 antagonist and methods of use
CN105263520B (zh) 包含抗cd38抗体和来那度胺的组合物
CN108348521A (zh) 用于治疗癌症的5-溴-2,6-二-(1h-吡唑-1-基)嘧啶-4-胺
JP7274426B2 (ja) 抗ｇｉｔｒアゴニスト抗体での癌の処置
CN114286828A (zh) 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法
CA2989144A1 (en) Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
JP2020023499A (ja) 抗ｃｘｃｒ４抗体によるｃ１０１３ｇ／ｃｘｃｒ４関連ワルデンシュトレームマクログロブリン血症の治療
JP6184952B2 (ja) 抗ｃｄ１９抗体とナイトロゲンマスタードとの併用療法
CN105407921A (zh) 包含抗cd38抗体和卡非佐米的组合物
JP2014525926A5 (enExample)
JP2024167261A (ja) 抗原結合タンパク質
WO2019067332A1 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER THROUGH A COMBINATION OF PROGRAMMED DEATH ANTIBODY ANTIBODIES (PD-1) AND A CXCR2 ANTAGONIST
JP2023538105A (ja) Ｃｄ４０アゴニスト抗体及び使用方法
WO2020033283A1 (en) Compositions and methods for treating cancer with a combination of programmed death receptor (pd-1) antibodies and vicriviroc
TW202222833A (zh) Cd40激動劑抗體和使用方法
HK1233518A1 (en) Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer
HK1249409B (en) 5-bromo-2,6-di-(1h-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171005

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20171018

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20171215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190611

R150 Certificate of patent or registration of utility model

Ref document number: 6541350

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees